Rivaroxaban versus standard anticoagulation for acute venous thromboembolism in childhood. Design of the EINSTEIN-Jr phase III study-Reference-Cited by-同舟云学术

Rivaroxaban versus standard anticoagulation for acute venous thromboembolism in childhood. Design of the EINSTEIN-Jr phase III study

Published:2018-12 Issue:1 Volume:16 Page:
ISSN:1477-9560
Container-title:Thrombosis Journal
language:en
Short-container-title:Thrombosis J

Author:

Lensing Anthonie W. A.,Male Christoph,Young Guy,Kubitza Dagmar,Kenet Gili,Patricia Massicotte M.,Chan Anthony,Molinari Angelo C.,Nowak-Goettl Ulrike,Pap Ákos F.,Adalbo Ivet,Smith William T.,Mason Amy,Thelen Kirstin,Berkowitz Scott D.,Crowther Mark,Schmidt Stephan,Price Victoria,Prins Martin H.,Monagle Paul

Funder

Bayer AG

Janssen Research and Development

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

http://link.springer.com/content/pdf/10.1186/s12959-018-0188-y.pdf

Reference41 articles.

1. Raskob GE, Angchaisuksiri P, Blanco AN, Buller H, Gallus A, Hunt BJ, et al. Thrombosis: a major contributor to global disease burden. Thromb Res. 2014;134:931–8.

2. Monagle P, Chan AK, Goldenberg NA, Ichord RN, Journeycake JM, Nowak-Göttl U, Vesely SK. Antithrombotic therapy in neonates and children: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e737S–801S.